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ABSTRACT
Coronavirus disease 2019 (COVID-19) is an infectious disease initially reported in 
China and currently worldwide dispersed caused by a new coronavirus (SARS-CoV-2 or 
2019-nCoV) affecting more than seven million people around the world causing more than 
400 thousand deaths (on June 8th, 2020). The diagnosis of COVID-19 is based on the clinical 
and epidemiological history of the patient. However, the gold standard for COVID-19 
diagnosis is the viral detection through the amplification of nucleic acids. Although the 
quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR) has been described 
as the gold standard for diagnosing COVID-19, there are several difficulties involving its 
use. Here we comment on RT-PCR and describe alternative tests developed for the diagnosis 
of COVID-19.
KEYWORDS: COVID-19. SARS-CoV-2. 2019-nCoV. RT-PCR. Serological methods. 
Immunochromatography.
INTRODUCTION
In December 2019, an outbreak of pneumonia of unknown etiology was reported 
in Hubei province, Wuhan municipality, China. In January 2020, the etiologic 
agent was isolated and described by the Chinese government as a new coronavirus 
(SARS-CoV-2 or 2019-nCoV)1-4. 
SARS-CoV2 is one of seven human-infecting coronaviruses identified so far. It is 
a single strand positive sense RNA virus (+)ssRNA belonging to the β-coronavirus 
lineage B1-3. In March 2020, the World Health Organization (WHO) declared the 
disease COVID-19, caused by SARS-CoV2, as a pandemic and according to WHO, 
there were more than seven million confirmed cases worldwide and more than 
400 thousand deaths (on June 8th, 2020)1,5.
SARS-CoV-2 genome codes for a polyprotein (ORF1ab) involved in the 
transcription and replication of the viral RNA, four structural proteins: E for envelope; 
M for membrane; N for nucleocapsid that is necessary for the viral synthesis and the 
S protein for Spike, that allows the entry and the infection of the host cell, in addition 
to five accessory proteins (ORF3a, ORF6, ORF7a, ORF8 and ORF10)1,3,6,7.
The viral S protein binds to the human ACE2 receptor, causing conformational 
changes in the coronavirus and allowing its fusion to the host cell membrane. The 
process of entering the cell requires the action of the TMPRSS2 protease, which 
regulates the cleavage of the S protein6,8. 
The clinical presentation of COVID-19 disease comprises a broad range of 
unspecified symptoms, such as fever, dry cough, dyspnea, headache, sputum 
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production, hemoptysis, myalgia, fatigue, nausea, vomiting, 
diarrhea and abdominal pain1,3,4,9,10. Loss of smell and 
taste were not commonly described in China, but have 
been reported more recently as an early clinical marker of 
COVID-1911,12. 
COVID-19 patients may be classified as asymptomatic 
or symptomatic, and the symptoms can vary from mild 
to severe and critical1,3,13. The severe acute respiratory 
syndrome (SARS) is more common among people with 
risk factors, such as advanced age, smoking and those 
with associated comorbidities (diabetes, hypertension, 
cardiovascular disease, obesity, chronic lung disease, kidney 
diseases)1,4,14. 
Once humans are infected, they begin to transmit 
the virus through droplets, sneezing, aerosols1,4,10. Some 
findings in the literature suggest that patients with none or 
only mild symptoms can release large amounts of viruses 
during the initial stage of the infection1,10,15,16, favoring the 
rapid spread of the virus1,10,14,17,18. However, Pan et al.19, 
in a study with 26 asymptomatic patients noticed that 
transmission by asymptomatic patients was less frequent 
than by symptomatic ones, suggesting that asymptomatic 
patients are less infectious.
The disease incubation period varies from 3-14 days, 
with an initial estimated basic reproduction number (R0) 
of 2.2, that is, each patient transmits the infection to 
other 2.2 individuals1,4. However, with the accumulated 
experience and higher numbers of patients in different 
countries, mathematical and epidemiological studies 
estimated COVID-19 R0 varying from 1.4 to 6.472,10,17, 
depending on the isolation and quarantine, as well as other 
control measures10,16.
Due to the high transmission rate of SARS-CoV2, 
specific measures are urgently needed to contain the 
pandemic, such as the improvement of diagnostic methods 
for the detection of asymptomatic and mildly symptomatic 
patients during the early phases of the disease. In this mini 
review, we summarize and discuss the diagnostic methods 
currently available1,2,14. 
Laboratory methods 
The diagnosis of COVID-19 is based on the clinical 
and epidemiological history of the patient, as well as on 
ancillary exams findings, for instance the chest X-ray and 
especially the chest tomography (CT-scan) revealing the 
characteristic images of ground glass, that were also seen 
in asymptomatic patients. However, the gold standard for 
COVID-19 diagnosis is through the analysis of nucleic 
acids, that is, the demonstration of SARS-CoV2 RNA in 
respiratory samples9,19-21. 
Non-specific exams 
Laboratory findings include leukopenia and lymphopenia 
in 80% of the cases, depletion of CD4 and CD8 lymphocytes, 
in addition to mild thrombocytopenia. Some authors have 
also suggested changes in the neutrophil/lymphocyte ratio in 
the severe disease progression of COVID-19 patients1,10,22. 
Increased inflammatory markers have also been 
described in COVID-19: lactate dehydrogenase (LDH), 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), aspartate aminotransferase (ASAT), troponin, 
ferritin, creatine kinase (CK) and D-dimer, in addition to 
the extended prothrombin time1,10,22. 
Severely ill patients may have high levels of cytokines 
IL2, IL4, IL6, IL7, IL10 and tumor necrosis factor 
(TNF)1,10,22. In patients with the severe acute respiratory 
syndrome, the so-called cytokines storms was observed, 
with the release of the previously mentioned cytokines in 
addition to others, such as CCL2, CCL3, CCL5, CXCL10, 
leading to multiple organs failure and eventually to 
death23-25. 
The quantitative Reverse-Transcription Polymerase 
Chain Reaction (RT-PCR)
In January 2020, the novel coronavirus was isolated 
from Wuhan’s patients providing information on the viral 
genetic sequencing, available at the Global Initiative 
on Sharing All Influenza Data – GISAID, allowing the 
development of the specific diagnostic methods for 
COVID-19 through quantitative Reverse-Transcription 
Polymerase Chain Reaction (RT-PCR) system, i.e, 
quantitative Real Time amplifications preceded by RNA 
extraction from the nasopharyngeal and oropharyngeal 
secretions, followed by a reverse transcription step to 
convert RNA into complementary DNA (cDNA) that will 
undergo amplification. The RT-PCRs that have been applied 
to COVID-19 diagnosis contain fluorescent probes that will 
recognize and hybridize to segments of the amplification 
products, increasing the assays specificity1,26,27. 
The RT-PCR is the gold standard for the confirmation 
of COVID-19 disease in upper respiratory samples 
(nasopharyngeal and oropharyngeal secretion). Several 
RT-PCR protocols were released by WHO to provide a 
suitable diagnosis, help testing populations and contribute 
to controlling the spread of the disease (Table 1)1,28. 
The RT-PCR protocol designed by the Institut Pasteur 
(France) showed excellent results in comparison with the 
protocol from Charité (Germany), considered the reference 
RT-PCR, reaching nearly 95% assertiveness in samples 
containing around 100 copies of SARS-CoV-2 genome. 
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In this protocol, two targets from the RNA-dependent 
RNA Polymerase (RdRP) gene of SARS-CoV-2 were 
evaluated separately (nCoV-IP2 and 4 – Table 1), and then 
the primers were combined in multiplex RT-PCR assays 
resulting in the detection of samples containing 10 copies 
of the virus genome29. The specificity was evaluated using 
samples containing other respiratory viruses (H1N1, H3N2, 
B-Victoria, B-Yamagata, influenza C, RSV A and B, hBoV, 
hPIV, hMPV, HRV/enterovirus, adenovirus, HKU1, OC43, 
229E and NL63) and none of them was detected with the 
RdRp gene/nCoV-IP2 and 429. 
Although RT-PCR has been described as the gold 
standard for diagnosing COVID-19, there are several 
difficulties involving its use1,10,23,28,30. The RT-PCR kit 
distributed by China’s CDC was designed to detect the 
nucleocapsid (N) and the Open Reading Frame ORF1ab 
of SARS- CoV-2 genome, and the infection is confirmed 
when both markers are amplified (Table 1). However, it is 
not infrequent that the results are inconsistent due to the 
amplification of only one of the targets10,23.
One of the bottlenecks related to RT-PCR for the 
diagnosis of COVID-19 is the incorrect collection and 
processing of samples. Some studies suggest that samples 
obtained from the upper respiratory tract (bottom of the 
nostrils and the oropharynx)1,9,10 are optimal clinical 
samples due the high viral copy number in the respiratory 
tract. In addition to oral and nasal swabs, viral load levels 
can be detected in the gastrointestinal tract and eventually 
in blood samples, however in lower amounts27,28,31.
A study performed by Yang et al.32, using different 
samples (throat swabs, nasal swabs, sputum and broncho 
alveolar lavage fluid – BALF) collected in different period 
of times (0 to 7, 8 to 14, and more than 15 days after the 
onset of disease) evidenced that except for BALF, sputum 
samples presented the highest positivity rate (74.4% and 
88.9%) , followed by nasal swabs (53.6% and 73.3%) from 
severely and mildly symptomatic patients in the first 14 days 
after the onset of disease, respectively. After 15 days of the 
onset of disease, sputum and nasal swabs presented lower 
positive rates (42.9% and 61.1%, respectively)32,33. BALF 
was considered important for monitoring and diagnosing 
severe cases, while throat swabs presented the lowest 
positivity among the samples32,33.
A report of two Korean patients found different viral 
load kinetics suggesting variations among infected people. 
In the first patient the virus was detected between two and 
three days after the onset of symptoms in both, the lower 
and the upper respiratory tract. However, viral load levels 
Table 1 - Description of the most used RT-PCR for diagnosing SARS-Cov-2. 
Institution/ country Primer ID Method Findings
China’s CDC – 
China29,56 
ORF1ab, E and N
Three singleplex RT-PCR using 
fluorescent-labeled probes 
Lowest detection limit of ORF1ab was 203 
copies/mL
Lowest detection limit of E gene was 664 
copies/mL
Lowest detection limit of N gene was 667 
copies/mL




Two singleplex RT-PCR or 
one multiplex RT-PCR with 
fluorescent-labeled probes
95% assertiveness in samples containing ~ 
100 viral copies 
The multiplex RT-PCR detects 10 viral copies 
No cross-reactivity with other viruses




Three singleplex RT-PCR using 
fluorescent-labeled probes
95% assertiveness in samples containing 
100,5 RNA copies/µL using automatic RNA 
extraction and 100 RNA copies/µL using manual 
RNA extraction
Charité – Germany29,58 
RdRP_SARSr
E_Sarbeco
Two singleplex RT-PCR, the 
screening made by the E gene 
amplification confirmed by 
RdRP
Lowest detection limit of RdRp and E_Sarbeco 
3.8 and 5.2 copies/reaction, respectively
HKU - Hong Kong29,59 
ORF1b-nsp14
N
Two RT-PCR, firstly the N gene 
amplification with fluorescent-
labed probe followed by 
confirmation by amplifying the 
ORF1b-nsp14 with fluorescent-
labeled probe
N gene Ct values up to 35.43 were positive 
corresponding to 15 copies/reaction
ORF1b Ct values up to 38.97 were positive 
corresponding to 1.5 copies/reaction 
National Institute of 
Health – Thailand29,59 
N
Singleplex RT-PCR with 
fluorescent-labeled probe
N gene Ct values were positive up to 38.12, 
corresponding to 15 copies/reaction
CDC = Center for Disease Control and Prevention; HKU = Hong Kong University.
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decreased on the 7th day, remaining positive until the 
13th day. In the second patient, the virus was detected on the 
14th day of symptoms in the lower and the upper respiratory 
tract, becoming undetectable from the 18th to 20th day, but 
coming back positive on the 25th day33. 
To ensure the best performance of the technique and to 
avoid RNA degradation, following the swabs collection, the 
samples are immersed in a transport medium/lysis buffer or 
a sterile saline solution1,29,31,34. Specimens should be stored 
at 2-8 °C for up to 72 h after sampling. When the test will not 
be performed in a short period of time, the samples should be 
stored at much lower temperatures, at least of -70 ° C29,34,35.
Another difficulty in carrying out RT-PCR is the delay 
in releasing results during the pandemic1,10. The RNA 
extraction step, part of the diagnostic protocol, is time 
consuming, especially if there is no automated platform 
to perform this process36,37, opening loopholes for the 
occurrence of cross-contamination between samples and of 
biological hazards to the handler, if the laboratory personnel 
is not using proper personal protection equipment when 
manipulating high viral load respiratory secretions28,38,39. 
Some studies have been carried out to shorten the 
diagnostic time using RT-PCR, and the results have shown 
that the RNA extraction step can be avoided in the diagnosis 
of COVID-1936,40. Grant et al.36 designed a RT-PCR to 
COVID-19 that do not undergo a previous RNA extraction 
step, and this procedure was compared with a high yield 
automated platform (Panther fusion Hologic) that reached 
98% sensitivity and 100% specificity. The authors concluded 
that the RT-PCR with no previous RNA extraction step has 
increased the performance of the technique. 
To reinforce this idea, Arumugam and Wong37, dealing 
with samples from influenza-suspected cases, demonstrated 
that the RNA extraction step is not necessary, provided that 
the patient’s nasal swab is immersed in a viral transport 
medium. These results were corroborated in samples from 
COVID-19 patients41,42. 
In addition to the previously mentioned difficulties related 
to RT-PCR, specific knowledge and specialized technical 
training are required to perform these amplifications, aside 
from the high costs of reagents and thermocyclers. The 
occurrence of RT-PCR false-positive results are associated 
with handling errors and cross-contamination of samples, 
while false-negative results are related to the incorrect 
sample collection, storage and processing1,10. 
Enzyme Immunoassay (EIA) or Enzyme-Linked 
immunosorbent Assay (ELISA) 
EIA or ELISA are simple, fast and safe assays that 
test serum or plasma samples from infected patients. The 
diagnosis through ELISA is based on the detection of IgM 
and IgG antibodies raised to SARS-CoV-2 nucleoprotein 
Rp3 during the initial stages of COVID-19 disease1,9,10. 
Coronavirus neutralizing antibodies target the S protein 
(Spike) that in turn mediates the entry of the virus into the 
host cell. The S1 subunit acts on the cell binding, while the 
S2 subunit acts on the fusion of the viral membrane to the 
cell membrane6,43. 
Okba et al.7 developed serological assays for the 
detection of neutralizing antibodies, as well as antibodies 
raised to the N and S proteins, as well as subunits S1 and 
the receptor-binding domain (RBD) from the S protein of 
SARS-CoV-2 through the ELISA method. These authors 
demonstrated that antibodies reacted with SARS-CoV-2 
proteins S, S1 and RBD, in addition to indicating S1 as the 
most specific antigen for the diagnosis of COVID-19. When 
evaluating the other domains of the protein S, they observed 
that the S2 subunit is the most conserved, playing a role 
in the cross-reactivity with the S protein of MERS-CoV. 
Reports in the literature suggest that false-positive 
ELISA results may occur with SARS-CoV-1 infection, 
as the protein N is extremely conserved among human-
infecting β-coronavirus1,10. 
Although the ELISA for the detection of protein S is 
more specific, in patients with mild infection, the proteins 
N and RBD were more sensitive than S1, indicating the 
need to detect antibodies against different antigens to avoid 
false-negative results1,7. 
The literature describes that IgM response to the S and 
N SARS-CoV-1 proteins peaks four weeks after the onset 
of symptoms, and is no longer detected three months after 
the onset of symptoms, while IgG detection was detected 
around the 14th day after the onset of symptoms, remaining 
detectable up to 36 months. In SARS-CoV-2, an study 
with 34 patients showed positivity for IgM and IgG on the 
3rd week after the onset of symptoms, with a decrease of 
IgM levels on the 4th week and increase of IgG from the 
4th week until the 7th week after the onset of symptoms44,45.
Guo et al.46 evaluated the humoral response against 
SARS-CoV-2 using an ELISA technique and plasma 
samples from 208 patients, 82 of whom had confirmed 
diagnosis of COVID-19 by RT-PCR, aside from samples of 
58 probable cases according to clinical signs and symptoms, 
although RT-PCRs had been negative. The results indicated 
that the mean duration of IgM and IgA antibodies was five 
days, while the IgG antibodies were detected 14 days after 
the onset of symptoms in those with RT-PCR-confirmed 
infections. 
These data showed that IgM detection by ELISA seems 
to be more efficient than RT-PCR five days after the onset of 
symptoms. Antibodies are known to have different temporal 
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dynamics, so that a combined assessment of IgG and IgM 
could increase the serological diagnosis sensitivity1,45,46. 
A study comparing the effectiveness of different 
commercially available serological tests showed 100% 
specificity of the Wantai SARS-CoV-2 total antibody 
ELISA (Beijing Wantai Biological Pharmacy Enterprise, 
Beijing, China), 93% for the Euroimmun IgA ELISA 
(Euroimmun Medizinische Labordiagnostika, Lϋbeck, 
Germany) and 96% for the Euroimmun IgG ELISA, 
with sensitivities of 90%, 90% and 65%, respectively, 
emphasizing the importance of combining tests raised to 
different antibodies1,47. 
Despite the advantages of using the ELISA technique, 
according to the CDC-USA, serological tests should not be 
used for diagnosing the acute phase of the disease (within 
7 days from the onset of symptoms); the serological method 
should be used for detecting possible previous infection 
in the convalescent phase, considering the period of 
14 days after the onset of symptoms; for the retrospective 
assessment of outbreaks, epidemiologic studies, screening, 
diagnosis of asymptomatic patients and close contacts of 
confirmed cases46,48,49.
Immunochromatographic tests (rapid tests) 
Aside from the ELISA assays, immunochromatographic 
tests have also been studied in the context of COVID-19. 
It is a quick test performed by the application of a drop of 
the patient’s sample (whole blood, serum or plasma) and 
a specific buffer on an immunochromatographic stick. By 
capillary attraction, the analyte of interest (a SARS-CoV-2 
protein or peptide) binds to its specific antibody in a 
reaction zone and the antigen-antibody reaction will be 
evidenced by the formation of a colored band (colloidal-
gold presenting a red color or colloidal selenium presenting 
a blue color). This reaction should always contain a test 
control (band that will always appear), together with one 
or two other bands; one band when the test detects total 
antibodies anti-SARS-CoV-2 and two bands when the test 
differentiates IgM and IgG antibodies50,51.
Pan et al.2 showed the effectiveness of the Colloidal-
Gold-Immunochromatographic Assay (GICA) technique 
for IgG and IgM anti-SARS-CoV-2 detections (Zhuhai 
Livzon Diagnostics Inc, Zhuhai, China), comparing results 
with those of RT-PCR. The sensitivity of GICA was 11.1% 
from the 1st to the 7th day after the onset of symptoms; 92.9% 
from the 8th to the 14th days and 96.8% from day 15 after 
the onset of symptoms. 
Whole blood samples, serum and plasma samples were 
evaluated using the GICA technique, and the detection of 
IgG and IgM antibodies was consistent irrespective of the 
biological sample, which is an advantage of the method 
considering the low viral load detected in blood samples 
by RT-PCR2,31. 
Some surveys have compared the GICA technique 
for the detection of IgG and IgM anti-SARS-CoV-2 with 
ELISA IgG and IgM, showing that both tests were 100% 
specific, but ELISA showed 87% sensitivity, while GICA 
reached 82.4%1,9. 
The Lateral Flow Immunoassay (LFIA) takes only 
15 min and the analysis of 397 patients with confirmed 
COVID-19 diagnosis by using the LFIA IgG and IgM 
showed 88.66% sensitivity and 90.63% specificity. When 
the results obtained from the analysis of blood sampled by 
digital punch, venous puncture, or using serum or plasma 
samples were compared, the results were consistent52. 
Immunochromatographic tests are a good option for 
diagnosing a large number of samples as it is fast, easy 
to perform, presenting sensitive results, allowing the 
identification of suspicious cases, as well as the screening 
and monitoring of COVID-19 progression in populations51.
Microarray
Microarray, a technique performed using small amounts 
of sample and reagents, is based on the detection of 
proteins from the specimen of interest by the recognition 
of antibodies immobilized on a surface, and the recognition 
is evidenced through the emission of a fluorescent signal 
that is captured and analyzed by a specific equipment53,54.
In a proteomic microarray using the genome of 
MN908947.3 (severe acute respiratory syndrome 
coronavirus 2 isolate Wuhan-Hu-1 complete genome 
sequence), to build the library containing 966 peptides 
as a reference, it was shown that the anti-SARS-CoV-1 
antibodies can also detect SARS-CoV-2 proteins, providing 
an alternative for the diagnosis of COVID-196. 
Wang et al.6 screened IgG and IgM antibodies in 
COVID-19 RT-PCR-positive patients via microarray and 
the technique revealed that many antibodies recognized the 
M, N, S, ORF1ab, ORF7a and ORF8 protein peptides. Four 
immune dominant epitopes were detected in more than 80% 
of the patients with confirmed diagnosis, namely: N (residue 
206-210, SPARM), S (residue 816-820, SFIED) and ORF3a 
(residue 136-140, KNPLL; residue 176-180, SPISE). No 
antibodies were detected for E, ORF6 and ORF10. 
Poh et al.55 analyzed 25 serum samples from patients 
with COVID-19 and they detected immunodominant 
B-cell epitopes. By depleting the antibodies directed to 
the epitopes S14P5, S21P2 and S14P5 + S21P2, a reduced 
ability to neutralize the SARS-CoV2-pseudovirus was 
observed. 
Oliveira et al.
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Experiments using the full length protein S 
revealed three main epitopes for the IgM antibody 
(816-SFIED-820; 886-WTFGA-890; 1046-GYHLM-1050) 
and six main epitopes for IgG antibody (26-PAYTN-30; 
186-FKNLR-190; 356-KRISN-360; 456-FRKSN-460; 
806-LPDPSKPSKRSFIED-820; 11196-SLIDL-1200). 
Within protein N, two main epitopes were selected for 
IgM detection (206-SPARM-210; 386-QKKQQ-390), 
and eight main epitopes for IgG detection (66-FPRGQ-70; 
96-GGDGK-100; 166-TLPKG-170; 206-SPARM-210; 
226-RLNQL-230; 256-KKPRQ-260; 316-GMSRI-320; 
366-TEPKKDKKKKADETQALPQRQKKQQTVTLPA
ADL-400)6. 
Microarray studies strongly suggest that this is an effective 
technique for mapping the antibodies profile, monitoring the 
immune response and identifying candidate epitopes for the 
development of diagnostic tests, vaccines and even new targets 
for treatment. The results have also confirmed that the receptor-
binding domain (RBD- residue 438-498) constitutes a good 
candidate for the development of neutralizing antibodies due 
to its action on ACE-2 receptors6,55. 
CONCLUSION 
Considering all the discussed points in this mini 
review, we conclude that many molecular and serological 
techniques have been developed so far, however, there is 
still urgent need of safe, fast, affordable, more sensitive 
and accurate methods for diagnosing the infection caused 
by SARS-CoV-2 to control the spread of COVID-19 and to 
enable the development of vaccines and specific treatments.
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